Syngeneic Models

Cancer immunotherapies are designed to work in conjunction with a patient's immune system to increase native anti-tumor responses. In this field of study, conventional xenograft models lack relevance due to the animals’ immunocompromised status. A syngeneic mouse model, however, provides an effective approach for studying how cancer therapies perform in the presence of a functional immune system.

Syngeneic Models in Cancer Immunotherapy

Learn how we can help you choose the best models to predict sensitivity to targeted therapies.

Watch now »

Charles River offers a broad range of syngeneic tumor models with well-characterized responses to known immune checkpoint inhibitors (e.g., anti-PDL-1, anti-PD-1 and anti-CTLA-4), making us the ideal partner to advance your immuno-oncology pipeline.

Now available! Use whole exome sequencing (WES) data to enhance your model selection, giving you the ability to choose based on mutation status as well as sensitivity to immune checkpoint inhibitors.

Request WES Information »

Histotype Cell Line
Bladder MBT-2
Breast 4T1, EMT-6
Colon Colon26, CT26, MC38
Lung KLN 205, Lewis Lung, Madison109
Lymphoma A20, E.G7-OVA
Melanoma B16F10, CloudmanS91
Pancreatic Pan02
Renal Renca

Histotype Cell Line
Hepatoma Yoshida
Leukemia C1498, L1210, P388
Lymphoma EL4
Mastocytoma P815
Plasmacytoma J558
Sarcoma EHS

*Note: Although these models have not yet been profiled for response to current standards of care, tumor growth curve data is available.

You may also be interested in...

Eureka Blog: Target Practice

The clinical success of cancer immunotherapy comes with a growing need for well-characterized preclinical models.

Poster Download

View our poster that outlines automated culture methods for PDX-derived tumor cells in natural extracellular 3D matrix.

Webinar Replay

View our webinar "Modulation of Tumor Progression by Immune Checkpoint Inhibitors in Syngeneic Murine Tumor Models."

Poster Download

View our poster that outlines our evaluation of the responsiveness of syngeneic models to two antibody-based immune checkpoint inhibitor therapeutics.